Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy

Core Viewpoint - Liminatus Pharma, Inc. has engaged Digital Offering LLC as its exclusive placement agent to explore innovative treasury-backed financing options to strengthen its capital structure [1][2][4] Group 1: Engagement and Strategy - The engagement with Digital Offering supports Liminatus's review of a digital asset treasury strategy, evaluating modern financial tools for capital structure enhancement [2][4] - The potential funding initiative may involve various exempt financing structures, including convertible debentures and equity-linked securities, compliant with U.S. securities laws [2][4] Group 2: Role of Digital Offering - Digital Offering is tasked with sourcing institutional and digital asset-focused investors and structuring a compliant financing solution for Liminatus [3][4] - The partnership aims to explore strategic funding opportunities in both traditional markets and the evolving digital asset landscape [4] Group 3: Company Overview - Liminatus is a preclinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies, advancing a pipeline of novel therapies [6] - The company is committed to responsible innovation in its capital strategy to support long-term scientific and operational objectives [6]